Detalhe da pesquisa
1.
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.
Blood Adv
; 8(11): 2846-2860, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598725
2.
Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia.
Cancer Gene Ther
; 29(11): 1751-1760, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35794338